Life Sciences and Healthcare

Top 10 oncology breakthroughs shared at ASCO 2021

Clarivate oncology experts analyzed more than 2,400 ASCO abstracts and selected the top 10 based on their expected impact on the drug treatment landscape. In the following article, we share our analysis of these exciting breakthroughs, data and takeaways for life sciences executives.   “Equity: Every Patient. Everyday. Everywhere” The ASCO Annual Meeting is the […]

Mainland China’s NRDL: The expensive yet priceless ticket to market access

Recent updates in the NRDL highlight Mainland China’s improving market access and reimbursement environment for innovative therapies. However, this comes at the cost of heavy price cuts that manufacturers must offer in exchange for NRDL inclusion. Are these price cuts worth gaining market access in Mainland China? What other trends have emerged from the recent […]

Drugs to Watch: What are the drivers and barriers for future blockbusters?

In this episode of Conversations in Healthcare, Mike Ward and market experts break down the opportunities and potential threats for 2021’s Drugs to WatchTM – – four drugs expected to be blockbusters by 2026.     Mike Ward: Hello. My name is Mike Ward, and welcome to Conversations in Healthcare, a podcast and video series […]

Amazon and Walmart wade into U.S. telehealth and digital pharmacy

The e–commerce giants’ evolving healthcare offerings could put pressure on drug makers, as well as PBMs and telehealth vendors Amazon’s healthcare ambitions have long been the subject of intense speculation – and not a little anxiety – for players throughout the sector. Amazon’s massive scale and world-beating digital capabilities give it the power to disrupt nearly any business it enters. So you could almost hear healthcare company CEOs taking a sharp breath and sitting up a little straighter when, in March, Amazon announced that it would offer its in-house health […]

State review boards take on drug prices amid Congressional inaction

How are states tackling high drug prices and increasing affordability? Clarivate market access expert Stephanie Hoops discusses the emergence of affordability review boards. Done waiting for Congress to take action on drug prices, states are increasingly enacting laws that create drug affordability review boards. As is done with utilities or insurance premiums, the boards allow states […]

Patient advocates speak out on partnering with life science companies

What does patient centricity mean from a patient’s point of view, and what kind of support do patient advocates need from life science companies? Three prominent patient advocates shared their perspectives. In 2010, Nick Sireau, a London-based father of two boys with the rare progressive genetic disease alkaptonuria (or AKU, also known as “Black bone […]

Best practices hospitals can adopt during vendor standardization: Q&A with Lori Goucher

In this interview, Lori Goucher, system clinical value analysis manager at Intermountain Healthcare, discusses best practices and success drivers in hospital vendor standardization.  The first step in reducing product variation and standardizing vendors is to define a strategy based on industry best practices and internal business intelligence. By pulling data from the organization’s multiple information […]

COVID-19 vaccines: Social media user sentiments and strategies to encourage administration

Although the pandemic continues to influence lives around the world, recent advances in vaccine development and distribution offer hope for relief. However, there is still uncertainty and misinformation surrounding the efficacy and safety of the vaccines. Clarivate experts Shubhita Thukraal and Vyshnavi Manda uncover consumer and healthcare worker attitudes based on analysis of social media […]